Condition

Non Small Cell Lung

ClinicalTrials.gov condition label

Clinical trials4

Recruiting1

Common interventions6

Lead sponsors shown4

Clinical trials

4 shown

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCCNCT07462377 · 2026-03-31

A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 MutationNCT02834936 · 2016-10-20

A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung CancerNCT00532155 · 2007-09-01

Clinical Impact of EUS in Staging NSCLCNCT00577746 · 2006-06-01

Common interventions

Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)DRUG1 Dexamethasone (pre- and post-medication for docetaxel)DRUG1 Docetaxel (Taxotere®)DRUG1 EPI-326DRUG1 PlaceboDRUG1 pyrotinibDRUG1

Leading sponsors

EpiBiologics1 Indiana University1 Jiangsu HengRui Medicine Co., Ltd.1 Sanofi1

Trial status mix

COMPLETED3

RECRUITING1

Phase mix

PHASE11

PHASE21

PHASE31

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.